Status:
COMPLETED
Sirolimus as Primary Therapy for the Treatment of Chronic Graft Versus Host Disease
Lead Sponsor:
Stanford University
Conditions:
Graft vs Host Disease
Blood and Marrow Transplant (BMT)
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
Evaluate the clinical activity of sirolimus in combination with cyclosporine and corticosteroids as first line therapy for the treatment of chronic Graft Versus Host Disease.
Detailed Description
An Open Label Study of Sirolimus as Primary Therapy for the Treatment of Chronic GVHD Following Allogeneic Bone Marrow Transplant
Eligibility Criteria
Inclusion
- active chronic GvHD
- ANC \> 1000/mm\^3
- therapeutic cyclosporine
Exclusion
- uncontrolled systemic infection
- elevated serum creatinine
Key Trial Info
Start Date :
January 1 1999
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2005
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00186667
Start Date
January 1 1999
End Date
September 1 2005
Last Update
April 9 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305